L
Luke Whitesell
Researcher at Massachusetts Institute of Technology
Publications - 75
Citations - 8817
Luke Whitesell is an academic researcher from Massachusetts Institute of Technology. The author has contributed to research in topics: HSF1 & Drug resistance. The author has an hindex of 36, co-authored 75 publications receiving 7756 citations. Previous affiliations of Luke Whitesell include University of Arizona & University of Toronto.
Papers
More filters
Journal ArticleDOI
HSP90 and the chaperoning of cancer.
TL;DR: Pharmacologically 'bribing' the essential guard duty of the chaperone HSP90 (heat-shock protein of 90 kDa) seems to offer a unique anticancer strategy of considerable promise.
Journal ArticleDOI
Heat shock factor 1 is a powerful multifaceted modifier of carcinogenesis.
TL;DR: It is reported that eliminating HSF1 protects mice from tumors induced by mutations of the RAS oncogene or a hot spot mutation in the tumor suppressor p53, and human cancer lines of diverse origins show much greater dependence onHSF1 function to maintain proliferation and survival than their nontransformed counterparts.
Journal ArticleDOI
HSF1 Drives a Transcriptional Program Distinct from Heat Shock to Support Highly Malignant Human Cancers
Marc L. Mendillo,Sandro Santagata,Sandro Santagata,Martina Koeva,George W. Bell,Rong Hu,Rong Hu,Rulla M. Tamimi,Rulla M. Tamimi,Ernest Fraenkel,Tan A. Ince,Luke Whitesell,Susan Lindquist +12 more
TL;DR: In this paper, the authors identify an HSF1-regulated transcriptional program specific to highly malignant cells and distinct from heat shock, which supports oncogenic processes: cell-cycle regulation, signaling, metabolism, adhesion and translation.
Journal ArticleDOI
Widespread Macromolecular Interaction Perturbations in Human Genetic Disorders
Nidhi Sahni,Song Yi,Mikko Taipale,Juan I. Fuxman Bass,Jasmin Coulombe-Huntington,Fan Yang,Fan Yang,Jian Peng,Jochen Weile,Jochen Weile,Georgios I. Karras,Yang Wang,István Kovács,István Kovács,Atanas Kamburov,Irina Krykbaeva,Mandy H. Y. Lam,George Tucker,Vikram Khurana,Amitabh Sharma,Amitabh Sharma,Yang-Yu Liu,Yang-Yu Liu,Nozomu Yachie,Nozomu Yachie,Quan Zhong,Yun Shen,Alexandre Palagi,Adriana San-Miguel,Changyu Fan,Dawit Balcha,Amélie Dricot,Daniel M. Jordan,Jennifer M. Walsh,Akash A. Shah,Xinping Yang,Ani K. Stoyanova,Alex Leighton,Michael A. Calderwood,Yves Jacob,Yves Jacob,Michael E. Cusick,Kourosh Salehi-Ashtiani,Luke Whitesell,Shamil R. Sunyaev,Shamil R. Sunyaev,Bonnie Berger,Albert-László Barabási,Albert-László Barabási,Benoit Charloteaux,David E. Hill,Tong Hao,Frederick P. Roth,Frederick P. Roth,Frederick P. Roth,Yu Xia,Yu Xia,Albertha J.M. Walhout,Albertha J.M. Walhout,Susan Lindquist,Susan Lindquist,Marc Vidal +61 more
TL;DR: This work functionally profile several thousand missense mutations across a spectrum of Mendelian disorders using various interaction assays, suggesting that disease-associated alleles that perturb distinct protein activities rather than grossly affecting folding and stability are relatively widespread.
Journal ArticleDOI
Harnessing Hsp90 function as a powerful, broadly effective therapeutic strategy for fungal infectious disease
Leah E. Cowen,Sheena D. Singh,Julia R. Köhler,Cathy Collins,Aimee K. Zaas,Wiley A. Schell,Hamza Aziz,Eleftherios Mylonakis,John R. Perfect,Luke Whitesell,Susan Lindquist +10 more
TL;DR: Hsp90 provides a much-needed strategy for improving the treatment of fungal disease because it enhances the efficacy of existing antifungals, blocks the emergence of drug resistance, and exerts broad-spectrum activity against diverse fungal pathogens.